CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $65.00. They now have a "buy" rating on the stock.
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CervoMed to Participate in Upcoming Investor Conferences
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024